Effect of lansoprazole on pharmacokinetics of nebivolol inhypertensive patients
Abstract
The present study was carried out to assess the pharmacokinetic drug interaction between nebivolol and lansoprazole following single oral dose administration in hypertensive patients. Therapeutic dose of nebivolol alone and combination with lansoprazole were administered to a separate group of hypertensive patients. Serial blood samples were collected at pre-dose (0.0) to 36 h post-dose following each treatment to characterize the pharmacokinetic parameters. The plasma nebivolol concentrations were estimated by a sensitive liquid chromatographic mass spectrometry (LC-MS) method. Mean (SD) of AUC0-t (ng.h/mL) and AUC0–∞ (ng.h/mL) for nebivolol given as a combination versus nebivolol alone is 34.08 (6.67) vs. 17.29 (4.60) and 43.36 (10.61) vs. 24.42 (5.08) respectively. Corresponding values for Cmax (ng/mL) is 6.37 (0.89) vs. 3.09 (0.37). Lansoprazole significantly increased the peak and extent of exposure of nebivolol when used in combination. There was minor change in the elimination parameters. The results indicate that there observed to be a pharmacokinetic interaction when nebivolol is administered in combination with lansoprazole. Hence, the combination is contraindicated or used with caution in a clinical situation
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.